The honest sermorelin before and after is a blood test, not a photo. Two weeks of GHRH 1-29 put IGF-1 back in the young-adult range in older men. We found no trial that has ever measured adult body composition on sermorelin.
The short answer. Sermorelin: The real “after” is a blood test. Two weeks of GHRH 1-29 restored IGF-1 to the young-adult range in older men (Corpas 1992) — the strongest measured result in the sermorelin literature.
- The rise plateaus by design. Intact feedback caps IGF-1 near the physiologic range; 16 weeks of nightly dosing sustained it without desensitization (Khorram 1997).
- Body composition was never measured in a modern sermorelin RCT. The class reference — tesamorelin’s -25 cm² visceral fat at 6 months — is CT-modest, not photo-dramatic.
- Sleep and recovery claims are mechanism-tier. Sermorelin-specific adult sleep and recovery outcomes are unquantified.
The honest sermorelin before-and-after is biochemical. In 1990s controlled studies, GHRH 1-29 brought IGF-1 back to the young-adult range within 14 days in older men, roughly a one-third rise. Nightly dosing held it there through 16 weeks. 0 RCTs since 2020 have tested adult body composition.
Quick answer
Here's what changes on sermorelin, per the published literature. GH pulses increase from the first dose. Serum IGF-1 rises within days, plateaus around weeks 2–4, and holds with continued dosing.
Body composition has never been measured in a modern sermorelin RCT. Sleep, recovery and “axis restoration” claims are mechanism-based rather than outcome-trial-validated.
What can a sermorelin before and after honestly mean?
No sermorelin trial ever photographed anyone. The before-and-after that exists in the literature is a set of measured endpoints.
Those endpoints are growth hormone pulse profiles and serum IGF-1, plus CT-measured fat area and DEXA-measured lean mass across the wider GHRH-analog class.
Sermorelin is the unmodified first 29 amino acids of native GHRH. It acts one step upstream of GH at the pituitary, with a half-life of roughly 10–20 minutes, per Memdouh and colleagues in 2021.
Identity, regulatory history and mechanism are covered in our complete sermorelin guide. This article is only about the time-course.
Sermorelin sits in an unusual evidence position. It was FDA-approved as Geref from 1997 to 2008, so the pharmacology is settled.
But that approval was pediatric, and the adult-use claims were never taken through controlled trials. The result is a molecule with real measured afters on biomarkers, and essentially none on the outcomes the marketing photos imply.
What happens in weeks 1–2 on sermorelin?
Sermorelin's earliest change is pharmacological. A GHRH-receptor agonist triggers a GH pulse within the first hour. That acute response is why sermorelin served as a diagnostic stimulation agent under the Geref label.
The most direct before-and-after experiment ever run on this molecule came in 1992. Corpas and colleagues gave healthy older men GHRH 1-29 subcutaneously twice daily for 14 days, then measured the GH axis. The finding is stated in the paper’s own title.
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
— trial title, Corpas et al., J Clin Endocrinol Metab, 1992.
Two weeks of dosing lifted 24-hour GH secretion and raised IGF-1 by roughly a third, back into the range typical of young adults, per Corpas and colleagues.
That's the strongest honest after in the entire sermorelin literature, and it's a blood test rather than a mirror. At day 14 the subjects looked identical to day 0.
The only noticeable changes in this window are the common early side effects: injection-site redness, transient flushing and mild water retention.
Why does the sermorelin IGF-1 rise plateau?
Sermorelin's IGF-1 rise plateaus by design. The peptide works through the intact hypothalamic–pituitary feedback loop, so rising IGF-1 and somatostatin push back on further GH release.
The elevation levels off near the young-adult range rather than escalating the way exogenous GH can. That physiologic ceiling is both the strongest argument for the GHRH-analog approach and the reason the after is inherently modest.
The longest well-controlled time-course comes from Khorram and colleagues, who gave older men and women a nightly GHRH 1-29 analog for 16 weeks.
The IGF-1 elevation appeared early and held through the full study, so the pituitary didn't desensitize. The accompanying endocrine and metabolic effects were modest rather than transformative, per Khorram and colleagues in 1997.
What does sermorelin do to body composition?
Nobody has measured it. Weeks 4 to 12 is the window every before-and-after photo implies, and it's exactly where the sermorelin-specific evidence stops.
There are 0 randomized controlled trials of sermorelin for adult body composition, performance or senescence endpoints since 2020. A 2026 Sports Medicine review by Mendias and Awan classifies its claimed benefits as mechanism-based rather than trial-validated.
The adult literature that does exist is conceptual. Sinha and colleagues in 2020 is the example: a review grouping GH secretagogues as candidate tools for body-composition management, not interventional data.
To calibrate what you should expect, look at the one GHRH analog with modern instrumented trials. In a 2024 randomized, double-blind substudy from Russo and colleagues, six months of tesamorelin cut CT-measured visceral fat by a median of 25 cm².
The comparison group gained 14 cm² over the same period, and liver fat fell 4.2 percentage points. That's what a real GHRH-analog after looks like at 6 months: meaningful on a CT scan, invisible across a room.
Sermorelin is a shorter-acting agonist at the same receptor. If it moves body composition at all, we'd expect that scale or smaller. Our tesamorelin vs sermorelin comparison works through why.
For unapproved peptides marketed for body composition and performance, sermorelin included, the claimed benefits rest on mechanism and biomarker change rather than on randomized-trial outcomes.
— summary of Mendias & Awan, Sports Medicine, 2026.
Do sermorelin’s sleep and recovery claims hold up?
Three longer-horizon sermorelin claims dominate the marketing, and none of them has an outcome trial. Each deserves its own honesty check.
Sleep. The mechanism is real. GHRH itself promoted slow-wave sleep in controlled polysomnography studies of healthy men, per Kerkhofs and colleagues in 1993, and altered sleep is among the most commonly reported subjective effects.
But that study used native GHRH in young adults. No modern sermorelin trial has quantified sleep-architecture outcomes in the populations the marketing targets.
Recovery and healing. Mechanism-only. GH and IGF-1 participate in tissue repair, but no controlled sermorelin trial has measured recovery, injury or musculoskeletal endpoints. Mendias and Awan say so plainly.
Axis restoration. The idea that sustained sermorelin use re-trains a flagging somatotropic axis traces largely to a 2006 opinion piece by Walker, proposing sermorelin as a more physiologic alternative to recombinant GH.
It's a coherent hypothesis, with pulsatility preserved and feedback intact, that has never been tested as a long-term outcome trial. We'd treat it as a rationale rather than a result, and so should you.
The class also cautions against assuming biomarker change cascades into felt outcomes. In a 2025 randomized trial of 73 patients, tesamorelin moved the measurable endpoints: waist circumference fell 2.7 cm versus standard of care.
The cognitive outcomes it was testing didn't improve, per Ellis and colleagues in 2025. A biomarker moving is the beginning of the question, not the answer.
Which sermorelin before-and-after claims does no trial support?
Five sermorelin claims appear routinely in promotions and are supported by no controlled trial, anywhere, at any date.
- Dramatic transformation photos. No sermorelin RCT has measured fat mass in adults; the only instrumented GHRH-analog fat data belongs to tesamorelin, and it is CT-modest.
- Visible lean-mass claims. No trial has shown appreciable lean-mass gain in healthy adults on any sermorelin protocol.
- “Look 10 years younger” skin reversal. No sermorelin study has measured skin endpoints.
- Guaranteed sleep transformation. Mechanistically plausible, never quantified for sermorelin in a modern trial.
- “Clinically proven” longevity-clinic claims. The clinical proof is a pediatric GHD approval that ended in 2008 plus two small 1990s biomarker studies — not an adult outcomes base.
Transformation photos carry a second, structural problem: you can't verify them, and they're confounded. Training, diet, other compounds and lighting all travel with the image, and so does simple selection, because only responders get photographed.
Here are the questions we'd ask of any sermorelin before-and-after claim.
- Is the change instrument-measured (IGF-1 assay, CT, DEXA, polysomnography) or photographic?
- Was there a control group, in a comparable population?
- Is the effect from sermorelin itself, or borrowed from tesamorelin or GH data?
- Does the claimed timeline match the pharmacology — biomarkers in weeks, composition in months, if at all?
- Who benefits from the claim, and would it survive the trial that has never been run?
Patients seeking sermorelin in 2026 should know they are using a molecule whose original therapeutic indication was abandoned for commercial reasons, not because it stopped working. They should also know that contemporary efficacy data for adult use is essentially absent.
— WTBP Research Team, editorial summary.
Where this leaves the stacking question
Because sermorelin’s own outcome data is thin, modern interest has migrated to combinations. Pairing a GHRH analog with a ghrelin-receptor agonist like ipamorelin lets two independent pathways drive a larger GH pulse.
Our GH-axis triple stack review examines that case. The short version: the combination logic is sound, and the human outcome data has the same gap documented here.
What to know now
- The real “after” is a blood test. Two weeks of GHRH 1-29 restored IGF-1 to the young-adult range in older men (Corpas 1992) — the strongest measured result in the sermorelin literature.
- The rise plateaus by design. Intact feedback caps IGF-1 near the physiologic range; 16 weeks of nightly dosing sustained it without desensitization (Khorram 1997).
- Body composition was never measured in a modern sermorelin RCT. The class reference — tesamorelin’s -25 cm² visceral fat at 6 months — is CT-modest, not photo-dramatic.
- Sleep and recovery claims are mechanism-tier. Sermorelin-specific adult sleep and recovery outcomes are unquantified.
- “Axis restoration” is a hypothesis from a 2006 opinion piece, never tested as a long-term outcome trial.
- Biomarker change is not outcome change. The 2025 Ellis trial moved the measurable endpoints and still missed its clinical one.
What we’re watching
We're watching two developments that would rewrite this timeline. First: any registered randomized trial of sermorelin with adult body-composition or sleep endpoints. A single instrumented 12-week study would replace most of this article’s inference with data, and nothing of the kind is in active enrollment.
Second: FDA compounding policy, which is narrowing the very channel that generated two decades of unmeasured adult use. If it closes, the before-and-after question may be answered by regulation rather than by a trial.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Sermorelin deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
The self-reports converge on sleep, not physique. Users describe deeper sleep and vivid dreams starting within the first week or two; vivid dreams come up in six separate comments across these threads, including u/bobbyocean5 at about one week in. Reports of body-composition change run in months rather than weeks, and the people reporting them are also dieting and lifting. Non-responders show up in three of the four experience threads checked, including a four-month user on TRT reporting "zero improvement in sleep, fat loss, muscle gain and sex drive." The community also splits on REM specifically: one Eight Sleep user reports REM "almost doubled," the opposite of the most-cited outside account. All of this is uncontrolled, unverified self-report, mostly from people simultaneously dieting, lifting, or on TRT, and none of it is measured against a control. VERIFIER'S NOTE — the submitted consensus was edited down in three places because it claimed more than the sources support: (1) "takes three to six months" was invented precision; the verified reports sit at two months (u/singlecut24) and four months (u/Aero808, u/Powerful-Cat-8087), so it now reads "months rather than weeks"; (2) "A large minority reports nothing at all" asserted a proportion nothing counts, so it now names where non-responders actually appear; (3) "several describe the sleep effect fading by month two or three" was REMOVED — it is not supported. Across all five threads (193 posts and comments) there is exactly one sermorelin comment about declining effectiveness, u/14hourstosave's anticipatory cycling remark ("can lead to"), which is not an observed fade, and one genuine tolerance report that is about DSIP, a different compound.
Where the community and the published record disagree. Three ways, with one caveat added and one softened after checking. First, the community's headline use is adult sleep, but sermorelin's FDA approval, as Geref, was for pediatric growth hormone deficiency and the product was off the US market by 2008. There is no approved adult sleep indication behind the thing people are buying it for. FLAG FOR THE EDITOR: none of the six community citations support this regulatory claim, and this pass could only corroborate it against secondary pages (GoodRx and vendor blogs), not a primary FDA record. Under this site's own standard it needs its own reference key before it is published as stated. The submitted version also said "only FDA approval was in 1997"; the sources found describe both a diagnostic and a treatment indication, so the narrower "only" wording is not safe to publish. Second, the threads treat it as close to side-effect free — "None. Only positive effects" is the top before-and-after post's own answer — while the most-cited outside account, Huberman's, reports the deep sleep arriving at the cost of REM plus a PSA rise that reversed on and off the compound: "It spiked my prostate-specific antigen. It was a very consistent effect. I came off it. It went back down, and it went back on. It went back up." Prostate-specific antigen is mentioned in ZERO of the 193 posts and comments across all five threads, so "no Reddit thread found mentions it" is verified. But the REM half of that contrast must be softened: the community is split on REM, not silent about it. u/RidiculousRonin, four months in, reports on an Eight Sleep that "my REM sleep almost doubled," and u/aapowell says it "always improves my deep and REM sleep." And Huberman caveats himself, which the page must carry or it overstates an n=1: "I know that there are some people who love sermorelin and don't see any of the same issues. It seems like it can be very individual." Third, the body-composition results are confounded by the users' own admission: the top comment (25 points, the highest in the thread) on the biggest four-month before-and-after post is "Honestly you need to give much more credit to your disciplined diet and exercise."
“I've been lifting 3x/ week and running 5k 2x/week on a 500 calorie deficit and I've never been this lean in my life. My sleep has improved drastically, especially deep sleep.”
“Been taking it for 4 months now (stacked with trt) and have seen zero improvement in sleep, fat loss, muscle gain and sex drive.”
“Sleep quality is out of this world ,and whoop confirms it”
“It nuked my rapid eye movement sleep in the second half of the night. It spiked my prostate-specific antigen. It was a very consistent effect.”
Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver (Huberman Lab)
“Very noticeable that I didn’t have excessive soreness and felt rested before gym sessions. Just know you’ll get best results from consistent use over a few months, consistency of dosing is key.”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Corpas, E., Harman, S. M., Piñeyro, M. A., et al. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. The Journal of Clinical Endocrinology & Metabolism, 75(2), 530–535. https://doi.org/10.1210/jcem.75.2.1379256
- Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle²⁷]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
- Kerkhofs, M., Van Cauter, E., Van Onderbergen, A., et al. (1993). Sleep-promoting effects of growth hormone-releasing hormone in normal men. American Journal of Physiology-Endocrinology and Metabolism, 264(4), E594–E598. https://doi.org/10.1152/ajpendo.1993.264.4.e594
- Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308. https://doi.org/10.2147/ciia.2006.1.4.307
- Russo, S. C., Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
- Ellis, R. J., Vaida, F., Hu, K., et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. The Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
- Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
- Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0